Malignant pleural effusion from lung adenocarcinoma treated by gefitinib

Internal Medicine

Volumn 50, Issue 7, 2011, Pages 745-748

  Kubo, Akihito ^a,b   Koh, Yasuhiro ^c   Kawaguchi, Tomoya ^a   Isa, Shun Ichi ^a   Okamoto, Isamu ^d   Fukuoka, Junya ^e   Kusunoki, Yoko ^a   Kitaichi, Masanori ^a   Takada, Minoru ^a   Nakagawa, Kazuhiko ^d  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOYAMA MEDICAL AND PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma; Gefitinib; Lung cancer; Malignant pleural effusion; Pharmacodynamics

Indexed keywords

CARBOPLATIN; GEFITINIB; K RAS PROTEIN; PACLITAXEL; VASCULOTROPIN RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; MALE; NICK END LABELING; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; THORAX DRAINAGE; THORAX RADIOGRAPHY; TREATMENT DURATION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRAINAGE; HUMANS; LUNG NEOPLASMS; MALE; PLEURAL EFFUSION, MALIGNANT; QUINAZOLINES; TREATMENT OUTCOME;

EID: 79953740723     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4652     Document Type: Article

References (14)

1. Fenton KN, Richardson JD. Diagnosis and management of malignant pleural effusions. Am J Surg 170: 69-74, 1995.
2. Sekine I, Sumi M, Saijo N. Local control of regional and metastatic lesions and indication for systemic chemotherapy in patients with non-small cell lung cancer. Oncologist 1 13 Suppl: 21-27, 2008.
3. Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 117: 73-78, 2000.
4. Heist RS, Christiani D. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 10: 59-68, 2009.
5. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
6. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110-124, 2002.
7. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23: 5323-5333, 2005.
8. Felip E, Rojo F, Reck M, et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 14: 3867-3874, 2008.
9. Rojo F, Tabernero J, Albanell J, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 24: 4309-4316, 2006.
10. Rothenberg ML, LaFleur B, Levy DE, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 23: 9265-9274, 2005.
11. Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65: 7276-7282, 2005.
12. The Japan Lung Cancer Society. General Rule for Clinical and Pathological Record of Lung Cancer. The 5th edition. Kanehara & Co., Ltd., Tokyo, 1999 (in Japanese).
13. Liou SY, Stephens JM, Carpiuc KT, Feng W, Botteman MF, Hay JW. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig 27: 381-396, 2007.
14. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14: 922-930, 2003.